Talazoparib - Pfizer
Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate; TALZENNALatest Information Update: 17 Jul 2024
At a glance
- Originator LEAD Therapeutics
- Developer Astellas Pharma; Big Ten Cancer Research Consortium; BioGene Pharmaceutical; Brown University; Calithera Biosciences; Center Trials & Treatment; Dana-Farber Cancer Institute; Epizyme; LifeSpan; National Cancer Institute (USA); Peter MacCallum Cancer Centre; Pfizer; St. Jude Childrens Research Hospital; Stanford University; Translational Research In Oncology; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center; Zenith Epigenetics
- Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; HER2 negative breast cancer; Prostate cancer
- Phase III Ovarian cancer
- Phase II Endometrial cancer; Fallopian tube cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Acute myeloid leukaemia
- No development reported Haematological malignancies; Myelodysplastic syndromes
Most Recent Events
- 31 May 2024 Pharmacodynamics data from the phase III TALAPRO-2 trial in Prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Updated efficacy and adverse events data from the phase I/II trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 02 Apr 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)